As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Benralizumab with mometasone furoate for treating severe nasal polyps.
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
| Status | Suspended |
| Decision | Selected |
| Process | TA |
| ID number | 1659 |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 April 2025 | Suspended. As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Benralizumab with mometasone furoate for treating severe nasal polyps. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 05 August 2024 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 16 March 2021 | The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of benralizumab for previously treated severe nasal polyps. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. Following an update from the company that market benralizumab, NICE will not be progressing with the scoping exercise at this stage. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience. |
For further information on our processes and methods, please see our CHTE processes and methods manual